Methadone is NOT a Contraindication to Spravato
Methadone is not listed as a contraindication to Spravato (esketamine nasal spray), and the two medications can be used together with appropriate monitoring and precautions. The FDA label for Spravato specifies only three absolute contraindications: aneurysmal vascular disease or arteriovenous malformation, history of intracerebral hemorrhage, and hypersensitivity to esketamine or ketamine 1.
Key Safety Considerations When Combining These Medications
Central Nervous System Depression Risk
Both methadone and Spravato can cause CNS depression, requiring heightened vigilance. Spravato causes sedation in 48-61% of patients and loss of consciousness in 0.3-0.4% of cases 1.
Mandatory 2-hour post-administration monitoring is required for all Spravato patients, with assessment of respiratory status including pulse oximetry 1.
Concomitant use of Spravato with CNS depressants (including opioids like methadone) requires close monitoring for enhanced sedation 1.
Respiratory Depression Monitoring
Postmarketing surveillance has identified rare cases of respiratory depression and respiratory arrest with Spravato, though the estimated incidence is approximately 1 case per 20,000 treatment sessions 2.
Respiratory monitoring including pulse oximetry must be performed throughout the 2-hour observation period when administering Spravato to patients on methadone 1.
Symptoms of respiratory depression are manageable and resolve with minor supportive measures when promptly identified 2.
QTc Prolongation Considerations
Both methadone and esketamine can potentially affect cardiac conduction, though this is primarily a concern with methadone at higher doses. Methadone doses above 120 mg daily may lead to QTc prolongation and torsades de pointes 3.
Baseline and follow-up ECG monitoring is recommended for patients on methadone doses >30-40 mg/day, particularly when adding other medications 3.
If combining Spravato with methadone in a patient with cardiac disease or on higher methadone doses, obtain baseline ECG and monitor for QTc prolongation 3, 4.
Clinical Management Algorithm
Pre-Treatment Assessment
Document current methadone dose and duration of therapy 3.
Obtain baseline ECG if methadone dose is >30-40 mg/day or patient has cardiac disease 3.
Assess for other CNS depressants that may compound sedation risk 1.
During Spravato Administration
Administer Spravato in a healthcare setting with continuous provider monitoring for 2 hours post-dose 1.
Monitor respiratory status including pulse oximetry throughout the observation period 1.
Assess for excessive sedation using standardized scales (Modified Observer's Assessment of Alertness/Sedation) 1.
Watch for dissociative symptoms, which occur in 61-84% of patients but typically resolve within 1.5 hours 1, 5.
Post-Treatment Criteria
Patient must be clinically stable before discharge, with resolution of acute sedation and dissociative effects 1.
Instruct patient not to drive or operate machinery until the next day after restful sleep 1.
Ensure patient has support person to accompany them home 1.
Common Pitfalls to Avoid
Do not assume methadone for opioid use disorder is a contraindication - Spravato can be used in patients with substance use disorders, and methadone may actually be preferred in these populations 3.
Do not skip the mandatory 2-hour observation period - This is a REMS requirement and critical for safety when combining with opioids 1.
Do not neglect cardiac monitoring in patients on higher methadone doses - The combination theoretically increases cardiac risk, though QTc prolongation with methadone is primarily dose-dependent 3.
Do not overlook the need for dose adjustment if excessive sedation occurs - Consider reducing Spravato dose from 84 mg to 56 mg if tolerability is an issue 1.
Evidence Quality Note
The FDA drug label provides the definitive guidance on contraindications 1, and methadone is notably absent from this list. The NCCN guidelines extensively discuss methadone safety but in the context of cancer pain management 3. No direct studies examine the methadone-Spravato combination, but the known pharmacology and monitoring requirements provide a framework for safe concurrent use 1, 2.